CD137, an attractive candidate for the immunotherapy of lung cancer.
Cancer Sci
; 111(5): 1461-1467, 2020 May.
Article
em En
| MEDLINE
| ID: mdl-32073704
ABSTRACT
Immunotherapy has become a hotspot in cancer therapy in recent years. Several immune checkpoints inhibitors have been used to treat lung cancer. CD137 is a kind of costimulatory molecule that mediates T cell activation, which regulates the activity of immune cells in a variety of physiological and pathological processes. Targeting CD137 or its ligand (CD137L) has been studied, aiming to enhance anticancer immune responses. Accumulating studies show that anti-CD137 mAbs alone or combined with other drugs have bright antitumor prospects. In the following, we reviewed the biology of CD137, the antitumor effects of anti-CD137 Ab monotherapy and the combined therapy in lung cancer.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral
/
Fatores Imunológicos
/
Imunoterapia
/
Neoplasias Pulmonares
/
Anticorpos Monoclonais
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article